The results showed that the median salivary anti-RBD IgA levels in noninfected individuals receiving two or three doses of inactivated whole-virion SARS-CoV-2 vaccine, one to three doses of mRNA vaccine or heterologous vaccination were lower than those after BTI or an mRNA vaccine booster after infection (Fig. 1A). The gene discussed is CD79A; the disease is infection.